Publications by authors named "Chelsea Kruger"
Article Synopsis
- * Methods: Over 48 weeks, 101 Black women (median age 35) were transitioned to the new regimen, and the study assessed retention rates, viral suppression, weight changes, and lipid panel improvements.
- * Results: Retention was high (92%), with over 90% maintaining viral suppression. Participants experienced an average weight gain of 2.7 kg and significant improvements in cholesterol and triglyceride
Background: Repeated COVID-19 waves and corresponding mitigation measures have impacted health systems globally with exceptional challenges. In response to the pandemic, researchers, regulators, and funders rapidly pivoted to COVID-19 research activities. However, many clinical drug studies were not completed, due to often complex and rapidly evolving research conditions.
View Article and Find Full Text PDFBackground: This exploratory study investigated four repurposed anti-infective drug regimens in outpatients with COVID-19.
Methods: This phase 2, single centre, randomised, open-label, clinical trial was conducted in South Africa between 3rd September 2020 and 23rd August 2021. Symptomatic outpatients aged 18-65 years, with RT-PCR confirmed SARS-CoV-2 infection were computer randomised (1:1:1:1:1) to standard-of-care (SOC) with paracetamol, or SOC plus artesunate-amodiaquine (ASAQ), pyronaridine-artesunate (PA), favipiravir plus nitazoxanide (FPV + NTZ), or sofosbuvir-daclatasvir (SOF-DCV).